Sue S R, Chari R S, Kong F M, Mills J J, Fine R L, Jirtle R L, Meyers W C
Department of Surgery, Duke University, Durham, North Carolina, USA.
Ann Surg. 1995 Aug;222(2):171-8. doi: 10.1097/00000658-199508000-00009.
The authors examined the expression of transforming growth factor-beta receptor (TGF-beta r) types I and II and the mannose 6-phosphate/insulin-like growth factor-II receptor (M6-P/IGF-IIr) in human hepatocellular carcinoma (HCC).
Transforming growth factor-beta (TGF-beta) is part of a superfamily of peptide-signaling molecules that play an important role in modulating cell growth. It is secreted as a latent complex and therefore, must be activated to elicit a biological response. Bioactivation of the TGF-beta complex is facilitated by binding to the M6-P/IGF-IIr. Once activated, TGF-beta exerts its effects by binding to specific cell membrane TGF-beta receptors. The loss of responsiveness of hepatocytes to TGF-beta has been implicated in hepatocarcinogenesis and could result from a loss in the expression of either the TGF-beta receptors or the M6-P/IGF-IIr.
Human hepatocellular carcinomas and surrounding normal tissue were collected from operating room samples and snap-frozen in liquid nitrogen (n = 13). Tissues from two tumors were fixed in Omni-fix for sectioning and immunohistochemistry staining for the M6-P/IGF-IIr and TGF-beta 1. RNA was extracted from both normal and malignant liver tissue and analyzed using an RNase protection assay. SDS-PAGE of purified membrane hybridized with 125I-TGF-beta 1 and 125I-IGF-II was used to determine the TGF-beta type I (TGF-betarI) and type II (TGF-beta rII) receptors and M6-P/IGF-IIr protein levels, respectively. Gels were quantitated by phosphorimager, and a paired t test was used for statistical analysis.
In HCC, a 60% (p < 0.01) and 49% (p < 0.02) reduction in the mRNA levels for T beta rI and T beta rII, respectively, relative to the receptor levels in surrounding normal liver, was shown. A similar decrease in the receptor protein levels also was observed. The M6-P/IGF-IIr mRNA and protein levels were reduced in 7 of 11 hepatocellular carcinomas. Immunohistochemical staining demonstrated an absence of intracellular TGF-beta 1 and reduced M6-P/IGF-IIr in the hepatocellular carcinoma cells.
These results demonstrate that human HCCs have a significantly reduced expression of both the TGF-beta rI- and TGF-beta rII-signaling receptors for TGF-beta. This may provide a selective growth advantage to the HCC by allowing them to escape the mito-inhibitory effects of activated TGF-beta. Furthermore, in the subset of HCC in which the expression of the M6-P/IGF-IIr is downregulated, the bioactivation of TGF-beta also may be impaired.
作者检测了转化生长因子-β受体(TGF-βr)I型和II型以及甘露糖6-磷酸/胰岛素样生长因子-II受体(M6-P/IGF-IIr)在人肝细胞癌(HCC)中的表达。
转化生长因子-β(TGF-β)是肽信号分子超家族的一部分,在调节细胞生长中起重要作用。它以潜伏复合物的形式分泌,因此必须被激活才能引发生物学反应。TGF-β复合物的生物激活通过与M6-P/IGF-IIr结合而促进。一旦被激活,TGF-β通过与特定的细胞膜TGF-β受体结合发挥其作用。肝细胞对TGF-β反应性的丧失与肝癌发生有关,可能是由于TGF-β受体或M6-P/IGF-IIr表达的丧失。
从手术室样本中收集人肝细胞癌及周围正常组织,并在液氮中速冻(n = 13)。将两个肿瘤的组织固定在全能固定液中用于切片以及对M6-P/IGF-IIr和TGF-β1进行免疫组织化学染色。从正常和恶性肝组织中提取RNA,并使用核糖核酸酶保护分析进行分析。用125I-TGF-β1和125I-IGF-II杂交的纯化膜进行SDS-PAGE,分别用于测定TGF-βI型(TGF-βrI)和II型(TGF-βrII)受体以及M6-P/IGF-IIr蛋白水平。通过磷光成像仪对凝胶进行定量,并使用配对t检验进行统计分析。
在HCC中,相对于周围正常肝组织中的受体水平,TβrI和TβrII的mRNA水平分别降低了60%(p < 0.01)和49%(p < 0.02)。在受体蛋白水平也观察到了类似的下降。11例肝细胞癌中有7例M6-P/IGF-IIr的mRNA和蛋白水平降低。免疫组织化学染色显示肝细胞癌细胞内不存在TGF-β1且M6-P/IGF-IIr减少。
这些结果表明,人HCC中TGF-β的TGF-βrI和TGF-βrII信号受体的表达均显著降低。这可能通过使它们逃避激活的TGF-β的有丝分裂抑制作用而赋予HCC选择性生长优势。此外,在M6-P/IGF-IIr表达下调子集的HCC中,TGF-β的生物激活也可能受损。